Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biopharmaceutical company focused on organ-selective medicines for respiratory and neurologic conditions, and the TBPH news feed highlights the company’s ongoing clinical, regulatory, commercial, and corporate developments. Company communications emphasize its role in the development of YUPELRI (revefenacin) inhalation solution, an FDA-approved once-daily nebulized LAMA for the maintenance treatment of COPD, and its late-stage investigational program with ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
News items for Theravance Biopharma commonly cover financial results and corporate updates, including quarterly earnings releases, collaboration revenue from YUPELRI, and commentary on operating discipline and capital allocation. Investors can also follow clinical development milestones, such as completion of enrollment in the Phase 3 CYPRESS study of ampreloxetine, the conclusion of open-label study periods, and anticipated timelines for topline data.
The TBPH news stream features scientific and medical conference activity, including platform and poster presentations on ampreloxetine at meetings like the International Symposium on the Autonomic Nervous System, as well as presentations and data on YUPELRI at respiratory congresses. In addition, Theravance Biopharma announces disease education initiatives such as the "Power in the Periphery" campaign and other efforts aimed at increasing awareness and understanding of nOH due to MSA among healthcare professionals.
Investors tracking TBPH can also see announcements about investor conferences and KOL events, where management and external experts discuss unmet medical needs in MSA-related nOH, review the ampreloxetine clinical program, and outline commercial strategies. For those following Theravance Biopharma stock, this news page provides a consolidated view of the company’s operational progress, scientific outreach, and key catalysts related to its respiratory and neurologic portfolios.
Theravance Biopharma (NASDAQ: TBPH) reported first-quarter 2024 financial results, highlighting YUPELRI® sales of $55.2 million, an 18% increase year-over-year. Collaboration revenue with Viatris rose by 39% to $14.5 million. The company's Q1 ending cash balance was $100 million. R&D and SG&A expenses decreased to $9 million and $16.7 million, respectively. Theravance also reported a net loss of $11.7 million, down from $22.1 million in Q1 2023. The company is progressing with the CYPRESS study for ampreloxetine and has a key opinion leader event scheduled for May 23, 2024.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference and host in-person meetings with investors. The event will include a Fireside Chat on May 20 at 11:30 AM EDT. A webcast will be available on Theravance.com for 30 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.